Monday, June 6, 2016

BRIEF-TG Therapeutics posts results from long-term follow-up of TGR-1202

* Term follow-up of TGR-1202 demonstrates a differentiated

safety profile and high response rates in CLL and NHL

Source text for Eikon:

Further company coverage:

(Bengaluru Newsroom: +1-646-223-8780)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)